To view this email as a web page, click here.
 
MEN'S HEALTH MONDAY
 
Enza plus ADT found beneficial regardless of chemo status
Adding enzalutamide (XTANDI) to androgen deprivation therapy significantly improves outcomes for men with metastatic hormone-sensitive prostate cancer regardless of whether they received prior chemotherapy.
Get the data
 
How do HIFU patients fare with salvage radiation?
Radiation is a well-tolerated and effective salvage option following primary high-intensity focal ultrasound for the treatment of localized prostate cancer, according to findings from a single-institution retrospective analysis.
Learn more
 
SURVEY
 
Is DRE still a relevant tool in the management of prostate cancer?
MORE FROM UROLOGY TIMES
 
Researchers develop noninvasive biomarker for aggressive PCa
Shock wave therapy: ED cure or unproven treatment?
JOB OPPORTUNITIES
 
NY-WNY Urology Associates
VT-University of Vermont
VT-University of Vermont
 
ADVERTISEMENT
Ad description here
 

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.